These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Intraductal papillary mucinous neoplasm of the pancreas - epidemiology, risk factors, diagnosis, and management. Aronsson L; Andersson R; Ansari D Scand J Gastroenterol; 2017 Aug; 52(8):803-815. PubMed ID: 28446039 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. Tesfaye AA; Philip PA Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899 [TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of pancreatic cancer. De La Cruz MS; Young AP; Ruffin MT Am Fam Physician; 2014 Apr; 89(8):626-32. PubMed ID: 24784121 [TBL] [Abstract][Full Text] [Related]
29. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819 [TBL] [Abstract][Full Text] [Related]
30. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479 [TBL] [Abstract][Full Text] [Related]
32. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698 [TBL] [Abstract][Full Text] [Related]
33. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596 [TBL] [Abstract][Full Text] [Related]
34. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Wang H; Zhao Q Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135 [No Abstract] [Full Text] [Related]
35. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Lee W; Yoon YS; Han HS; Jang JY; Cho JY; Jung W; Kwon W; Choi Y; Kim SW World J Surg; 2017 Feb; 41(2):562-573. PubMed ID: 27834017 [TBL] [Abstract][Full Text] [Related]
36. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. de Geus SW; Bliss LA; Eskander MF; Ng SC; Vahrmeijer AL; Mahadevan A; Kent TS; Moser AJ; Callery MP; Bonsing BA; Tseng JF J Gastrointest Surg; 2016 Jan; 20(1):85-92; discussion 92. PubMed ID: 26427374 [TBL] [Abstract][Full Text] [Related]
38. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521 [TBL] [Abstract][Full Text] [Related]
39. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. Kang CM; Choi JY; Seong JS; Song SY; Lee WJ; Kim MJ; Chung JB Pancreas; 2012 Apr; 41(3):467-73. PubMed ID: 22158068 [TBL] [Abstract][Full Text] [Related]